Variables | Patients with AS | Controls |
---|---|---|
No. | 122 | 122 |
Sex (male) | 88 (72.1%) | 88 (72.1%) |
Age at recruitment, yrs | 37.5 ± 12.4a | 37.5 ± 12.0 |
Laboratory test | ||
Leukocyte count (103/μl) | 7.1 (1.0–15.7)b,c | 6.2 (3.8–9.7) |
HLA-B27+ | 110 (90.2%) | |
ESR, mm/h | 19.0 (12.0–34.0)b | |
CRP, mg/dl | 0.42 (0.12–1.20)b | |
Clinical characteristics | ||
Age at symptom onset, yrs | 24.0 (20.0–35.0)b | |
Disease duration, yrs | 7.0 (2.0–14.0)b | |
Delayed diagnosis, yrs | 0.0 (0.0–2.0)b | |
Clinical syndromes | ||
Peripheral arthritis | 36 (29.5%) | |
Uveitis | 29 (23.8%) | |
Inflammatory bowel disease | 4 (3.3%) | |
BASDAI | 4.2 (2.5–5.9)b | |
BASFI | 1.3 (0.2–3.6)b | |
BAS-G | 4.8 (2.0–6.5)b | |
mSASSS | 10.0 (4.0–20.0)b |
↵a Mean ± SD.
↵b Data were presented as median (Q1–Q3).
↵c p < 0.01; Wilcoxon rank sum test. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BAS-G: Bath Ankylosing Spondylitis Global; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score.